Your browser doesn't support javascript.
loading
Efficacy of neoadjuvant pertuzumab in addition to chemotherapy and trastuzumab in routine clinical treatment of patients with primary breast cancer: a multicentric analysis.
Fasching, Peter A; Hartkopf, Andreas D; Gass, Paul; Häberle, Lothar; Akpolat-Basci, Leyla; Hein, Alexander; Volz, Bernhard; Taran, Florin-Andrei; Nabieva, Naiba; Pott, Birgit; Overkamp, Friedrich; Einarson, Hanna; Hadji, Peyman; Tesch, Hans; Ettl, Johannes; Lüftner, Diana; Wallwiener, Markus; Müller, Volkmar; Janni, Wolfgang; Fehm, Tanja N; Schneeweiss, Andreas; Untch, Michael; Pott, Dirk; Lux, Michael P; Geyer, Thomas; Liedtke, Cornelia; Seeger, Harald; Wetzig, Sarah; Hartmann, Arndt; Schulz-Wendtland, Rüdiger; Belleville, Erik; Wallwiener, Diethelm; Beckmann, Matthias W; Brucker, Sara Y; Kolberg, Hans-Christian.
Afiliação
  • Fasching PA; Department of Gynecology and Obstetrics, Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich Alexander University of Erlangen-Nuremberg, Universitätsstrasse 21-23, 91054, Erlangen, Germany. peter.fasching@uk-erlangen.de.
  • Hartkopf AD; Department of Obstetrics and Gynecology, University of Tübingen, Tübingen, Germany.
  • Gass P; Department of Gynecology and Obstetrics, Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich Alexander University of Erlangen-Nuremberg, Universitätsstrasse 21-23, 91054, Erlangen, Germany.
  • Häberle L; Department of Gynecology and Obstetrics, Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich Alexander University of Erlangen-Nuremberg, Universitätsstrasse 21-23, 91054, Erlangen, Germany.
  • Akpolat-Basci L; Biostatistics Unit, Department of Gynecology and Obstetrics, Erlangen University Hospital, Erlangen, Germany.
  • Hein A; Marienhospital Bottrop, Bottrop, Germany.
  • Volz B; Department of Gynecology and Obstetrics, Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich Alexander University of Erlangen-Nuremberg, Universitätsstrasse 21-23, 91054, Erlangen, Germany.
  • Taran FA; Department of Gynecology and Obstetrics, Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich Alexander University of Erlangen-Nuremberg, Universitätsstrasse 21-23, 91054, Erlangen, Germany.
  • Nabieva N; Department of Obstetrics and Gynecology, University of Tübingen, Tübingen, Germany.
  • Pott B; Department of Gynecology and Obstetrics, Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich Alexander University of Erlangen-Nuremberg, Universitätsstrasse 21-23, 91054, Erlangen, Germany.
  • Overkamp F; Marienhospital Bottrop, Bottrop, Germany.
  • Einarson H; Oncologianova GmbH, Recklinghausen, Germany.
  • Hadji P; Department of Obstetrics and Gynecology, University of Tübingen, Tübingen, Germany.
  • Tesch H; Frankfurter Hormon und Osteoporosezentrum Goethestrasse, Goethestr.23, Frankfurt, Germany.
  • Ettl J; Oncology Practice, Bethanien Hospital, Frankfurt am Main, Germany.
  • Lüftner D; Department of Obstetrics and Gynecology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.
  • Wallwiener M; Department of Hematology, Oncology and Tumor Immunology, Charité University Hospital, Campus Benjamin Franklin, Berlin, Germany.
  • Müller V; Department of Obstetrics and Gynecology, University of Heidelberg, Heidelberg, Germany.
  • Janni W; Department of Gynecology, Hamburg-Eppendorf University Medical Center, Hamburg, Germany.
  • Fehm TN; Department of Gynecology and Obstetrics, Ulm University Hospital, Ulm, Germany.
  • Schneeweiss A; Department of Gynecology and Obstetrics, Düsseldorf University Hospital, Düsseldorf, Germany.
  • Untch M; National Center for Tumor Diseases and Department of Gynecology and Obstetrics, Heidelberg University Hospital, Heidelberg, Germany.
  • Pott D; Department of Gynecology and Obstetrics, Helios Clinics Berlin-Buch, Berlin, Germany.
  • Lux MP; Onkologische Schwerpunktpraxis Bottrop, Bottrop, Germany.
  • Geyer T; Department of Gynecology and Obstetrics, Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich Alexander University of Erlangen-Nuremberg, Universitätsstrasse 21-23, 91054, Erlangen, Germany.
  • Liedtke C; Department of Gynecology and Obstetrics, Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich Alexander University of Erlangen-Nuremberg, Universitätsstrasse 21-23, 91054, Erlangen, Germany.
  • Seeger H; Department of Gynecology and Breast Center, Charité University Hospital, Campus Mitte, Berlin, Germany.
  • Wetzig S; Department of Obstetrics and Gynecology, University of Tübingen, Tübingen, Germany.
  • Hartmann A; Marienhospital Bottrop, Bottrop, Germany.
  • Schulz-Wendtland R; Institute of Pathology, Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich Alexander University of Erlangen-Nuremberg, Erlangen, Germany.
  • Belleville E; Institute of Diagnostic Radiology, Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich Alexander University of Erlangen-Nuremberg, Erlangen, Germany.
  • Wallwiener D; ClinSol GmbH & Co KG, Würzburg, Germany.
  • Beckmann MW; Department of Obstetrics and Gynecology, University of Tübingen, Tübingen, Germany.
  • Brucker SY; Department of Gynecology and Obstetrics, Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich Alexander University of Erlangen-Nuremberg, Universitätsstrasse 21-23, 91054, Erlangen, Germany.
  • Kolberg HC; Department of Obstetrics and Gynecology, University of Tübingen, Tübingen, Germany.
Breast Cancer Res Treat ; 173(2): 319-328, 2019 Jan.
Article em En | MEDLINE | ID: mdl-30324275
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Anticorpos Monoclonais Humanizados / Trastuzumab Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: Breast Cancer Res Treat Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Alemanha
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Anticorpos Monoclonais Humanizados / Trastuzumab Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: Breast Cancer Res Treat Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Alemanha